<VariationArchive VariationID="234993" VariationName="NM_000169.3(GLA):c.1125_1140del (p.Val376fs)" VariationType="Deletion" Accession="VCV000234993" Version="13" RecordType="classified" NumberOfSubmissions="4" NumberOfSubmitters="4" DateLastUpdated="2024-07-15" DateCreated="2016-06-03" MostRecentSubmission="2024-02-20">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="236819" VariationID="234993">
      <GeneList>
        <Gene Symbol="GLA" FullName="galactosidase alpha" GeneID="2717" HGNC_ID="HGNC:4296" Source="submitted" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>Xq22.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="X" Accession="NC_000023.11" start="101397803" stop="101407925" display_start="101397803" display_stop="101407925" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="X" Accession="NC_000023.10" start="100652778" stop="100663000" display_start="100652778" display_stop="100663000" Strand="-" />
          </Location>
          <OMIM>300644</OMIM>
          <Haploinsufficiency last_evaluated="2021-03-24" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=GLA">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2021-03-24" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=GLA">No evidence available</Triplosensitivity>
          <Property>gene_acmg_incidental_2013</Property>
          <Property>gene_acmg_incidental_2016</Property>
          <Property>gene_acmg_incidental_2021</Property>
          <Property>gene_acmg_incidental_2022</Property>
        </Gene>
        <Gene Symbol="RPL36A-HNRNPH2" FullName="RPL36A-HNRNPH2 readthrough" GeneID="100529097" HGNC_ID="HGNC:48349" Source="calculated" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>Xq22.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="X" Accession="NC_000023.11" start="101391011" stop="101414133" display_start="101391011" display_stop="101414133" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="X" Accession="NC_000023.10" start="100645877" stop="100669127" display_start="100645877" display_stop="100669127" Strand="+" />
          </Location>
        </Gene>
      </GeneList>
      <Name>NM_000169.3(GLA):c.1125_1140del (p.Val376fs)</Name>
      <CanonicalSPDI>NC_000023.11:101397958:AGGATTACAGGCCACT:</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>Xq22.1</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="X" Accession="NC_000023.11" start="101397959" stop="101397974" display_start="101397959" display_stop="101397974" variantLength="16" positionVCF="101397958" referenceAlleleVCF="CAGGATTACAGGCCACT" alternateAlleleVCF="C" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="X" Accession="NC_000023.10" start="100652947" stop="100652962" display_start="100652947" display_stop="100652962" variantLength="16" positionVCF="100652946" referenceAlleleVCF="CAGGATTACAGGCCACT" alternateAlleleVCF="C" />
      </Location>
      <HGVSlist>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000169.2" sequenceAccession="NM_000169" sequenceVersion="2" change="c.1125_1140delAGTGGCCTGTAATCCT">
            <Expression>NM_000169.2:c.1125_1140delAGTGGCCTGTAATCCT</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000023.10" sequenceAccession="NC_000023" sequenceVersion="10" change="g.100652947_100652962del" Assembly="GRCh37">
            <Expression>NC_000023.10:g.100652947_100652962del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000023.11" sequenceAccession="NC_000023" sequenceVersion="11" change="g.101397959_101397974del" Assembly="GRCh38">
            <Expression>NC_000023.11:g.101397959_101397974del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_007119.1" sequenceAccession="NG_007119" sequenceVersion="1" change="g.14990_15005del">
            <Expression>NG_007119.1:g.14990_15005del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000169.3" sequenceAccession="NM_000169" sequenceVersion="3" change="c.1125_1140del" MANESelect="true">
            <Expression>NM_000169.3:c.1125_1140del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000160.1" sequenceAccession="NP_000160" sequenceVersion="1" change="p.Val376fs">
            <Expression>NP_000160.1:p.Val376fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_672" sequenceAccession="LRG_672">
            <Expression>LRG_672:g.14990_15005del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="non-coding">
          <NucleotideExpression sequenceAccessionVersion="NR_164783.1" sequenceAccession="NR_164783" sequenceVersion="1" change="n.1204_1219del">
            <Expression>NR_164783.1:n.1204_1219del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001619" Type="non-coding transcript variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001199973.2" sequenceAccession="NM_001199973" sequenceVersion="2" change="c.300+2502_300+2517del">
            <Expression>NM_001199973.2:c.300+2502_300+2517del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001627" Type="intron variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001199974.2" sequenceAccession="NM_001199974" sequenceVersion="2" change="c.177+6137_177+6152del">
            <Expression>NM_001199974.2:c.177+6137_177+6152del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001627" Type="intron variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000169.2" sequenceAccession="NM_000169" sequenceVersion="2" change="c.1125_1140del16">
            <Expression>NM_000169.2:c.1125_1140del16</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef ID="CA10581189" DB="ClinGen" />
        <XRef Type="rs" ID="876661347" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000169.3(GLA):c.1125_1140del (p.Val376fs) AND not provided" Accession="RCV000223751" Version="5">
        <ClassifiedConditionList TraitSetID="9460">
          <ClassifiedCondition DB="MedGen" ID="C3661900">not provided</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2015-07-27" SubmissionCount="2">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000169.3(GLA):c.1125_1140del (p.Val376fs) AND Fabry disease" Accession="RCV000806628" Version="12">
        <ClassifiedConditionList TraitSetID="3012">
          <ClassifiedCondition DB="MedGen" ID="C0002986">Fabry disease</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2021-07-15" SubmissionCount="2">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2021-07-15" NumberOfSubmissions="4" NumberOfSubmitters="4" DateCreated="2016-06-03" MostRecentSubmission="2024-02-20">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic</Description>
        <DescriptionHistory Dated="2018-05-29">
          <Description>Pathogenic/Likely pathogenic</Description>
        </DescriptionHistory>
        <ConditionList>
          <TraitSet ID="3012" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="1790" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Fabry's disease</ElementValue>
                <XRef ID="Fabry+Disease/2690" DB="Genetic Alliance" />
                <XRef ID="16652001" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Ceramide trihexosidosis</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Fabry disease</ElementValue>
                <XRef ID="MONDO:0010526" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Angiokeratoma, diffuse</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Anderson-Fabry disease</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hereditary dystopic lipidosis</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Alpha-galactosidase A deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">GLA deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Angiokeratoma corporis diffusum</ElementValue>
                <XRef ID="HP:0001071" DB="Human Phenotype Ontology" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Ceramide trihexosidase deficiency</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="disease mechanism" integerValue="273">loss of function</Attribute>
                <XRef ID="GTR000556520" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000591289" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528276" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000507480" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520414" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000551442" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000512526" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520063" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000514924" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000568367" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000596367" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000558532" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000552214" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000505068" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000507942" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528536" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000522527" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528516" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528500" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528528" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000325415" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000556501" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000246735" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520447" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000260631" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="6400" />
                <XRef ID="6400" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="disease mechanism">Fabry disease is due to inactivating mutations in the X-linked GLA gene resulting in deficiency of the enzyme Alpha Galactosidase-A.</Attribute>
                <XRef ID="GTR000500007" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Fabry disease is the most common of the lysosomal storage disorders and results from deficient activity of the enzyme alpha-galactosidase A (α-Gal A), leading to progressive lysosomal deposition of globotriaosylceramide and its derivatives in cells throughout the body. The classic form, occurring in males with less than 1% α-Gal A enzyme activity, usually has its onset in childhood or adolescence with periodic crises of severe pain in the extremities (acroparesthesia), the appearance of vascular cutaneous lesions (angiokeratomas), sweating abnormalities (anhidrosis, hypohidrosis, and rarely hyperhidrosis), characteristic corneal and lenticular opacities, and proteinuria. Gradual deterioration of renal function to end-stage renal disease (ESRD) usually occurs in men in the third to fifth decade. In middle age, most males successfully treated for ESRD develop cardiac and/or cerebrovascular disease, a major cause of morbidity and mortality. Heterozygous females typically have milder symptoms at a later age of onset than males. Rarely, females may be relatively asymptomatic throughout a normal life span or may have symptoms as severe as those observed in males with the classic phenotype. In contrast, late-onset forms occur in males with greater than 1% α-Gal A activity. Clinical manifestations include cardiac disease, which usually presents in the sixth to eighth decade with left ventricular hypertrophy, cardiomyopathy, arrhythmia, and proteinuria; renal failure, associated with ESRD but without the skin lesions or pain; or cerebrovascular disease presenting as stroke or transient ischemic attack.</Attribute>
                <XRef ID="NBK1292" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301469</ID>
                <ID Source="BookShelf">NBK1292</ID>
              </Citation>
              <Citation Type="general">
                <ID Source="pmc">3009617</ID>
              </Citation>
              <Citation Type="general" Abbrev="HFSA, 2010">
                <ID Source="PubMed">20610207</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2002">
                <ID Source="PubMed">12735292</ID>
              </Citation>
              <Citation Type="general" Abbrev="Eng et al., 2006">
                <ID Source="PubMed">16980809</ID>
              </Citation>
              <Citation Type="general" Abbrev="Salviati et al, 2010">
                <ID Source="pmc">2869001</ID>
              </Citation>
              <Citation Type="Translational/Evidence-based" Abbrev="EuroGentest, 2011">
                <ID Source="PubMed">21934708</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23788249</ID>
              </Citation>
              <Citation Type="general" Abbrev="AHA/ASA, 2014">
                <ID Source="PubMed">25355838</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2013">
                <ID Source="PubMed">23860966</ID>
              </Citation>
              <Citation Type="general" Abbrev="ESC, 2014">
                <ID Source="PubMed">25173338</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2015">
                <ID Source="PubMed">25356965</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2016">
                <ID Source="PubMed">27854360</ID>
                <ID Source="DOI">10.1038/gim.2016.190</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <Citation Type="general" Abbrev="AHA/ACC/HFSA, 2022">
                <ID Source="PubMed">35378257</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACC/AHA/HFSA, 2017">
                <ID Source="PubMed">28461259</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Fabry.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Decreased a-galactosidase A, Fabry Disease, 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Fabry-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Alpha-galactosidase A (alpha- gal A) Deficiency, 2022</CitationText>
              </Citation>
              <XRef ID="324" DB="Orphanet" />
              <XRef ID="C0002986" DB="MedGen" />
              <XRef ID="MONDO:0010526" DB="MONDO" />
              <XRef Type="MIM" ID="301500" DB="OMIM" />
              <XRef Type="primary" ID="HP:0001071" DB="Human Phenotype Ontology" />
            </Trait>
          </TraitSet>
          <TraitSet ID="9460" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="17556" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">not provided</ElementValue>
                <XRef ID="13DG0619" DB="Department Of Translational Genomics (developmental Genetics Section), King Faisal Specialist Hospital &amp; Research Centre" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">none provided</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">The term 'not provided' is registered in MedGen to support identification of submissions to ClinVar for which no condition was named when assessing the variant. 'not provided' differs from 'not specified', which is used when a variant is asserted to be benign, likely benign, or of uncertain significance for conditions that have not been specified.</Attribute>
              </AttributeSet>
              <XRef ID="C3661900" DB="MedGen" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="528590" SubmissionDate="2016-05-06" DateLastUpdated="2016-06-03" DateCreated="2016-06-03">
        <ClinVarSubmissionID localKey="NM_000169.2:c.1125_1140del16|Not provided" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000280104" DateUpdated="2016-06-03" DateCreated="2016-06-03" Type="SCV" Version="1" SubmitterName="Stanford Center for Inherited Cardiovascular Disease, Stanford University" OrgID="505443" OrganizationCategory="clinic" OrgAbbreviation="SCICD" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2015-10-15">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Likely pathogenic</GermlineClassification>
          <Comment>Note this variant was found in clinical genetic testing performed by one or more labs who may also submit to ClinVar. Thus any internal case data may overlap with the internal case data of other labs. The interpretation reviewed below is that of the Stanford Center for Inherited Cardiovascular Disease. GLA p.Val376ProfsX10 Given that this is a loss of function variant in a gene where loss of function variants are known to cause disease and the absence of this type of variant in the general population, we consider this variant likely pathogenic. The variant has not been reported with disease before. The variant is in the 7th and last exon. This mutation is expected to result in an abnormal, truncated protein product by replacing the last 54 amnio acids with 9 incorrect amino acids. There are 11 frameshift GLA vairants in ClinVar, all are listed as pathogenic but only one has multiple submitters. Of note, only one of these variants is more distal than this variant. However, multiple other frameshift mutations downstream of this position in the GLA gene have been reported in HGMD in association with Fabry disease (Stenson P et al., 2014). There are 23 nonsense GLA variants in ClinVar, all are listed as pathogenic, three have multiple submitters. The location of the V376PfsX10 variant, in the last exon of the gene, makes it unlikely to be subject to nonsense mediated decay; rather, it would produce a misfolded protein with a shortened polypeptide chain. Several truncation variants downstream of the V376PfsX10 variant have been reported in association with classic Fabry disease: Q386X, W399X (Mol Med. 1997 Mar; 3(3): 174–182.); E398X (Am J Hum Genet. 1993 Dec;53(6):1186-97.) In addition, exon 7 is the site of ~30% of small deletions and duplications &lt; 65 nucleotides, according to data collected though the Fabry Outcome Survey Registry and review of the literature (Acta Paediatr Suppl. 2005 Mar;94(447):87-92; D. Elstein et al (eds) Fabry Disease, DOI 10.1007/978-90-481-9033-1_1). The variant isn't present in the Exome Aggregation Consortium dataset (http://exac.broadinstitute.org/), which currently includes variant calls on ~64,000 individuals of European, African, Latino and Asian descent (as of October 13, 2015). There are also no other loss of function variants.However, it is important to note that a deletion of this size could be missed with ExAC's methods. Nonetheless, no nonsense variants or smaller indels are present in this dataset.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="1" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GLA" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000169.2:c.1125_1140del16</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Not provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>5_6_2016</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="561961" SubmissionDate="2019-01-29" DateLastUpdated="2018-05-03" DateCreated="2016-07-24">
        <ClinVarSubmissionID localKey="GDX:493358|Not Provided" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000293042" DateUpdated="2018-05-03" DateCreated="2016-07-24" Type="SCV" Version="9" SubmitterName="GeneDx" OrgID="26957" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2015-07-27">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>Although the c.1125_1140del16 mutation in the GLA gene has not been reported to our knowledge, this pathogenic variant causes a shift in reading frame starting at codon Valine 376, changing it to a Proline, and creating a premature stop codon at position 10 of the new reading frame, denoted p.Val376ProfsX10. This variant is expected to result in an abnormal, truncated protein product by replacing the last 54 amnio acids with 9 incorrect amino acids. Multiple other frameshift mutations downstream of this position in the GLA gene have been reported in HGMD in association with Fabry disease (Stenson P et al., 2014). Furthermore, the c.1125_1140del16 variant was not observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations.In summary, c.1125_1140del16 in the GLA gene is interpreted as a disease-causing variant</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">GeneDx Variant Classification (06012015)</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/dhtz9flo/genedx_interprules_final_061215.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GLA" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000169.2:c.1125_1140del16</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Not Provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB5098196</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1840672" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-20" DateCreated="2019-08-14">
        <ClinVarSubmissionID localKey="5749509|MedGen:C0002986" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000946637" DateUpdated="2024-02-20" DateCreated="2019-08-14" Type="SCV" Version="6" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2019-02-05">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>This sequence change results in a premature translational stop signal in the GLA gene (p.Val376Profs*10). While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 40 amino acids of the GLA protein. This variant is not present in population databases (ExAC no frequency). For these reasons, this variant has been classified as Pathogenic. This variant disrupts the p.Pro409 amino acid residue in GLA. Other variants that disrupt this residue have been observed in individuals with GLA-related conditions (PMID:¬†12428061,¬†21598360, 11668641, 12428061, Invitae), suggesting that it is a clinically significant residue. As a result, variants that disrupt this residue are likely to be causative of disease. Experimental studies and prediction algorithms are not available for this variant, and the functional significance of the affected amino acids is currently unknown. This variant has been observed in an individual affected with Fabry disease¬†(Invitae).¬†¬†ClinVar contains an entry for this variant (Variation ID:¬†234993).</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GLA" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000023.10:g.100652947_100652962del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0002986" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11431369</SubmissionName>
          <SubmissionName>SUB12508014</SubmissionName>
          <SubmissionName>SUB14200314</SubmissionName>
          <SubmissionName>SUB8755776</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="4028248" SubmissionDate="2022-01-10" DateLastUpdated="2022-01-12" DateCreated="2022-01-12">
        <ClinVarSubmissionID localKey="NM_000169.3:c.1125_1140del|OMIM:301500" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002054370" DateUpdated="2022-01-12" DateCreated="2022-01-12" Type="SCV" Version="1" SubmitterName="Genome-Nilou Lab" OrgID="507598" OrganizationCategory="laboratory" OrgAbbreviation="Genome Nilou" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-07-15">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>no</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GLA" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000169.3:c.1125_1140del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="301500" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB10918493</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="1840672" TraitType="Disease" MappingType="XRef" MappingValue="C0002986" MappingRef="MedGen">
        <MedGen CUI="C0002986" Name="Fabry disease" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="561961" TraitType="Disease" MappingType="Name" MappingValue="Not Provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="528590" TraitType="Disease" MappingType="Name" MappingValue="Not provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4028248" TraitType="Disease" MappingType="XRef" MappingValue="301500" MappingRef="OMIM">
        <MedGen CUI="C0002986" Name="Fabry disease" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

